just reading through the announcement...
Initial highlights are...
Stirling Products is currently in advanced negotiation for:
• acquisition of a $30 million near new, fully licensed pharmaceutical production facility on extra-ordinary terms
• over $5 million in government grants
…. and positioned for:
• significant sales revenues – commencing next 3 – 6 months
• targeted cash flow breakeven by mid 2010
• targeted annualised sales revenue of min $30M by end 2010
The market for herbal and botanical products is forecast to grow by over 168% over the next 5 years to over US$33 billion
• Over 60% of all New Chemical Entities for prescription pharmaceuticals in the last 5 years have been derived from natural or synthesized natural sources
ImmunoXel has demonstrated in all its clinical trials that it:
• is a powerful immunomodulator and adjuvant
• substantively tunes the Immune System
• enhances efficacy of - antibiotics, viral therapies
and chemotherapies
• can substantially shorten drug and chemotherapy
treatment duration
• can reduce and reverse treatment toxicity
side-effects – esp. in liver and kidneys
• is market ready for treatment of TB, TB/HIV, AIDS
• over 800 patients treated in clinical trials
– mainly TB, TB/HIV but also AIDS and influenza
• Enhances efficacy of drugs 2-10 fold
• Shortens therapy duration 3-12 fold
• Reduces and reverses toxicity of current TB drugs
World Health Organisation estimates (2007) over 1 million people in each of India and China have TB ( page 15)
Estimated Number of People Living with HIV/AIDS,(2007) over 30 million ( page 17)
There are plenty more pages of info in the presentation that I expect will spark some interest in India
- Forums
- ASX - By Stock
- STI
- market price sensitive information
market price sensitive information, page-3
-
- There are more pages in this discussion • 83 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add STI (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online